About Us

Immune Targeting Systems (ITS) is a London based biotech company developing synthetic vaccines for mutating viruses underpinned by its DepoVaccine™ and HighDensity (HD) Antigen™ identification technology platforms. ITS’s lead programme is a synthetic universal influenza vaccine targeting all potential seasonal and pandemic flu strains and is currently in phase-I clinical testing in the UK. The company has commenced lead optimization of its universal Hepatitis-B therapeutic vaccine targeting all major viral genotypes (A, B, C & D).

Mutating viruses (Influenza-A, Hepatitis-B & C, HIV) cause major global disease problems and are responsible for some the world greatest epidemics and pandemics.These viruses are known to have originally jumped species from animals to humans.The process of human host immunity & tendency of the virus to make errors in its replication drives the mutation process. Mutation typically takes place on the viruses’ surface permitting it to evade the body’s primary defence mechanism – antibody immunity. Antibody immunity is the key outcome for currently available vaccine technologies.

The DepoVaccine™ T-cell vaccine technology represents a breakthrough in T-cell vaccine design, learning key lessons from its predecessor T-cell vaccine technologies. This next generation, long synthetic peptide based T-cell vaccine technology’s key objective is to promote a robust second line of immunological defence targeting all viral strains & mutants, whatever your genetic or ethnic background.

---